Mass Spec Shops Rely on New Software to Gain Edge in Competitive Biomarker Space | GenomeWeb

Biomarkers were on the minds — or at least in the press releases — of a number of vendors at last week's American Society for Mass Spectrometry conference in San Antonio. This emerging area of the proteomics sector is viewed as a key driver for growth in the mass-spec market over the next decade, and several vendors who launched new biomarker-discovery platforms at ASMS told ProteoMonitor's sister publication, BioInform, that bioinformatics will be the key to their success in this competitive environment.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

Biomedical research projects are generating a ton of data that still needs to be analyzed, NPR reports.

Theranos is retiring some of its board members, including Henry Kissinger and George Shultz, Business Insider reports.

The heads of 29 scientific societies and some 2,300 researchers call on President-elect Donald Trump to rely on and support science in two separate letters.

In Science this week: genetically modified flu virus could be key to new live vaccines, and more.